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Primary cutaneous follicle center lymphoma is an indolent primary cutaneous B-cell lymphoma originating from the
follicle center cells, composed of a combination of centrocytes (small and large cleaved cells) and centroblasts
(large noncleaved cells) with a follicular, follicular/diffuse, or diffuse growth pattern. Lesions are mostly located on
the head, neck and trunk. A case is presented of a 56-year-old male patient with primary cutaneous follicle center
lymphoma, with lesions involving the skin of the back, shoulders, presternal area and right forearm. As the patient
presented a disseminated cutaneous form of the disease that involved several anatomical regions, complete work-up
was followed by superficial fractionated radiotherapy of eight fields in VI expositions, with total irradiation dose of
1400 cGy upon the following fields: right and left pectoral region, left and right shoulders, right suprascapular region,
and proximal third of the right forearm. Total irradiation dose applied upon each field for the lesions located on the left
and right side of the back was 1500 cGy. This therapy resulted in significant reduction of visible tumor. The patient was
regularly followed up on outpatient basis for 12 months of radiotherapy, being free from local recurrence and systemic
spread of the disease.
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Primary cutaneous follicle center lymphoma (PCFCL) can
be defined as neoplastic proliferation of the follicle germinal
center cells limited to the skin. PCFCL is a primary
cutaneous B-cell lymphoma composed of neoplastic B-cells
with morphological and immunophenotypic properties of
follicle center cells, usually a combination of centrocytes
(small and large cleaved center cells) and a variable number
of centroblasts (large noncleaved follicle center cells with
prominent nucleoli). According to growth pattern, it is
divided into follicular, diffuse and mixed pattern. This
type of lymphoma is described as a separate entity in
the WHO-EORTC classification of primary cutaneous
lymphomas [1], as well as in the new WHO classification
of hematopoietic and lymphoid tissue tumors [2]. The
diagnosis of PCFCL is made in 11% of all patients with
cutaneous lymphomas [1].* Correspondence: romana.ceovic@zg.htnet.hr
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reproduction in any medium, provided the orAll cutaneous lymphomas require complete work-up
including staging in order to rule out extracutaneous
lymphoma of similar morphology [3]. Disease staging
includes physical examination, laboratory testing, chest
x-ray, ultrasonography (US) of lymph nodes and visceral
organs, computed tomography (CT) of the chest, abdomen
and pelvis, and bone marrow biopsy. Besides complete
disease history, making an accurate diagnosis requires
histopathology, immunophenotyping and molecular
studies.
When extracutaneous disease has been excluded by
complete work-up, the diagnosis of primary cutaneous
lymphoma can be made [1,4]. Fluorodeoxyglucose-positron
emission tomography (FDG-PET), recently increasingly
employed, can be performed as an additional study, along
with bone marrow biopsy [5,6]. As comparison of FDG-
PET and bone marrow biopsy findings showed no major
differences in their accuracy and specificity, the authors
concluded that FDG-PET could be used as an additional
study to bone marrow biopsy, in the work-up of malignant
lymphoma in particular [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A 56-year old male patient with numerous
erythematous and livid infiltrates before superficial
radiotherapy.
Figure 2 A 56-year old male patient with numerous
erythematous and livid infiltrates before superficial
radiotherapy.
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association with Borrelia burgdorferi, hepatitis C or
human herpesvirus 8 infection has been occasionally
described [8-11]. In the majority of cases, adults of both
sexes are affected, whereas PCFCL is rare in childhood
[12]. Clinical picture is characterized by the occurrence
of solitary or grouped erythematous papules, plaques
and tumor lesions, mostly non-ulcerated. The lesions are
usually localized in the head, neck and trunk areas, less
frequently on lower extremities [13-15]. The lesions
localized on the back were in the past known as Crosti
lymphoma or reticulohistiocytoma of the back [14].
There is no strict differentiation in clinical picture and
localization of follicular and diffuse PCFCL; however, the
former are predominantly found in the head and neck
region, and the latter on the trunk [16,17]. Generally,
PCFCL is a localized disease rarely associated with
extracutaneous dissemination [18].
The histopathologic picture of PCFCL varies depending
on the duration, stage of lesion growth as revealed by
biopsy specimen, and localization [15,19]. Most slides
show nodular to diffuse infiltrates with normal epidermis.
Minor and initial lesions contain a mixed picture of
centrocytes, some centroblasts, and less reactive T cells.
Large centrocytes are characteristic of PCFCL. Large
neoplastic B-cells may resemble fibroblasts. Follicular
growth can be clearly observed in minor and/or initial
lesions. Well differentiated diffuse PCFCL lesions involve
the entire dermis, frequently spreading to the subcutane-
ous adipose tissue. The lesions are characterized by prolif-
eration of small, medium-sized and large cleaved cells
(centrocytes) admixed with a variable number of large
cells with morphological characteristics of centroblasts.
Small reactive T lymphocytes are mostly intertwined with
tumor cells. Histologic slide with biopsy specimen of a
lesion with follicular growth pattern may mimick follicular
extracutaneous lymphoma [17,20]. PCFCL with follicular
growth is composed of nodular infiltrates in the dermis,
usually with subcutaneous tissue involvement, characteriz-
ing the follicular growth basis. If present, neoplastic follicles
show morphological abnormalities such as reduced or
absent mantle cell zone, reduced or completely absent
stained body macrophages, and monomorphous pheno-
menon without clearly delineated dark and light areals.
Cytomorphologically, neoplastic follicles consist of small
and large centrocytes linked to centroblasts, frequently
mixed with small reactive lymphocytes. In some cases,
both diffuse and follicular growth characteristics are found
in the same tumor; residual follicles are seen on the
infiltrate periphery, while diffuse growth predominates in
the central part. The morphological variants of PCFCL
showing nodules of medium-sized centrocytes mixed with
centroblasts without prominent interfollicular infiltrate
were earlier known as large-cell lymphocytoma [21,22].As the tumor lesion grows, neoplastic B lymphocytes also
grow and replicate, while the number of reactive T cells is
on a decrease [15,19]. The stromal component is usually
very pronounced.
In case of either diffuse or neoplastic PCFCL, neoplastic
cells are positive for CD20 and CD79a B-cell markers. In
most cases of PCFCL with diffuse growth characteristics,
cells are CD10- and without a network of CD21 follicular
dendritic cells in the background. In contrast, in PCFCL
with follicular growth cells are positive for CD10 and Bcl-
6 markers [17,23-25]. The presence of small CD10+ and/
or Bcl-6+ clusters outside the neoplastic follicles may be
occasionally seen [17]. This phenomenon caused by ‘active
migration’ of neoplastic follicular cells from the follicles
toward the interfollicular space and back, has been de-
scribed in nodal follicular lymphomas [26]. Other markers
Figure 3 The epidermis is preserved, with diffuse and nodular
infiltrates of lymphoid cells. (H&E, magnification 40×).
Figure 4 The infiltrate is composed of atypical, medium-sized
and focally large lymphatic cells. (H&E, magnification 400×).
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germinal center, such as paired box gene (PAX)-5 gene
and interferon regulatory factor (IRF) 8, however, other
B-cells are also positive for these markers [27]. On the
slides with visible diffuse and follicular growth features,
CD21+ follicular dendritic cells are located in the
periphery of larger areals with a diffuse growth pattern.
Residual network of CD21 follicular dendritic cells is
mostly found within neoplastic follicles. Unlike nodal
follicular lymphoma, expression of bcl-2 is generally
rare [17,27,28]. Bcl-2 positive cells are infrequently
found in PCFCL, localized within the follicular center in
10%-15% of cases and only rarely in the entire neoplastic
population [17,27,29-35]. Multiple myeloma oncogene-1
(MUM-1) is positive in less than 30% of PCFCL cells
[36]. Polyclonal plasma cells with no restriction of κ
and λ chains are frequent in patients with cutaneous
lymphoma [17,37].
In most cases, PCFCL shows monoclonal distribu-
tion of the JH gene, but also a reduced detection of this
distribution by the PCR method. This might be, at least in
part, due to the high number of somatic hypermutations
characteristic of this tumor. Somatic hypermutations of
variable heavy and light chains can be observed, con-
firming this lymphoma to originate from the follicular
center cells [38,39]. Numerous literature data clearly
demonstrate that PCFCL generally is not associated with t
(14;18) translocation [17,27,40-44]. The presence of t
(14;18) translocation is characteristic of systemic fol-
licular lymphomas and part of systemic diffuse large
cell B-lymphomas [25,28,29,40].
Inactivity of the p15 and p16 tumor suppressor genes
may be detected in 10%-30% of cases [45]. In most
patients with solitary or multiple lesions generally localized
on the head and trunk, therapy of choice is radiotherapy
based on histologic classification according to the growth
pattern and number of blast cells, and the prognosis is
good in these patients [1,4,13-15,46-51]. Radiotherapy is
first-line therapy also for tumor lesions with histologi-
cally predominant large cleaved cells [48,50,52-55]. Skin
relapses, seen in 20% of patients, which do not readily
suggest disease progression, can also be treated with
radiotherapy [56]. In case of localized skin lesions,
excision of tumor lesions should be considered, followed
by radiotherapy of the operative field and adjacent skin
[15]. Chemotherapy is indicated for extensive and spread
skin lesions and in patients developing extracutaneous
disease [17,52]. Systemic and intralesional interferon α, or
in combination with other therapeutic procedures, can
also be taken in consideration [57-61].
Recent studies report on therapeutic results recorded
with systemic or intralesional anti-CD20 antibody therapy
in PCFCL patients [62-68]. Rituximab (anti-CD20 anti-
body) can be therapeutically combined with systemicchemotherapy in patients with generalized skin disease,
extracutaneous disease, or relapsing cutaneous lesions
[69]. Taking the growth pattern, blast cell count, and
presence of solitary or multiple cutaneous lesions into
consideration, PCFCL has a good prognosis with 5-year
survival of about 95% [4,13-15,17,29,46-49]. There is no
substantial prognosis difference between tumor lesions
with a follicular growth pattern and tumor lesions with
AB
Figure 5 Immunohistochemical staining for CD20 demonstrates diffusely positive reaction in tumour cells (A: IHC, CD20, magnification
20×), coexpressing BCL6 (B: IHC, BCL6, magnification 400×).
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that poorer prognosis should be expected in PCFCL
cases with diffuse growth pattern, pronounced bcl-2
expression and histologically visible large cells [70].
In spite of the possible occurrence of local relapses,
seen in some 20% of cases, extracutaneous dissemination
of the disease is uncommon. There are only rare cases of
disease dissemination to the central nervous system [70].
Case presentation
A 56-year-old male patient presented to our Department
for cutaneous lesions that had first appeared four years
before. Clinical picture included numerous erythematous
and erythematous-livid infiltrates, 2–8 cm in diameter,
on his upper back, shoulders, in the presternal region
and in the proximal third of his right forearm [Figures 1
and 2]. There was no enlargement of the palpable lymph
nodes and the patient denied any subjective discomforts
of pain or itch. He had been treated for type 2 diabetesFigure 6 Post-radiotherapy appearance.mellitus and arterial hypertension for years and regulary
checked for multipli naevi pigmentosi on the trunk.
Laboratory findings: complete blood count, urine, blood
glucose, liver enzymes, bilirubin, urea, creatinine, lipid
profile, creatine kinase, lactate dehydrogenase, C-reactive
protein, protein electrophoresis, immunoglobulins, and
serum Cu were within the reference values. Serology for
hepatitis C and B viruses and Borrelia burgdorferi [5-8],
and HIV-ELISA produced negative findings.
Biopsy specimens were obtained from lesions on the left
shoulder, the back and the right shoulder. Histopathology
of all three specimens revealed superficially regular,
preserved epidermis and diffuse full-depth lymphocyte
infiltration of the excised dermis [Figure 3]. In the deep
dermis, there was abundant lymphocytic infiltrate with
the formation of follicular germinal center and the
surrounding ‘mantle zone’. The infiltrate was composed of
atypical, medium-sized and focally large lymphatic cells
[Figure 4].Figure 7 Post-radiotherapy appearance.
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sized and focally large lymphatic cells to be CD20+,
bcl-6+, bcl-2 weakly positive, CD10-, MUM1-, CD3- and
CD5- [Figure 5A,B]. Staining for κ and λ chains demon-
strated rare polyclonal plasma cells peripherally. Staining
for CD21 showed the follicular dendritic network to be
preserved and focally extended.
Clonal B lymphocyte population was demonstrated by
molecular analysis using the PCR method with analysis
of rearrangement in the gene for immunoglobulin heavy
chain and the gene for immunoglobulin light chain of
kappa type (IgK).
Considering the histologic picture and verified clonality,
the finding corresponded to the skin infiltration with
B-immunophenotype lymphoma, requiring further exclusion
of extracutaneous lymphoma [1,3,4].
The patient was referred to a hematologist; based on
hematologic examination and the findings available, the
hematologist suggested ruling out systemic disease and
recommended bone marrow biopsy and multi-slice com-
puted tomography (MSCT).
Bone marrow biopsy revealed no evidence of tumor.
MSCT of the thorax, abdomen and pelvis showed no
lymphadenopathy, however, visualizing multiple concre-
ments up to 8 mm in size in the cholecyst.
Upon complete work-up, and considering the histologic
picture, verified clonality and exclusion of extracutaneous
spread of the disease, the finding was consistent with the
picture of PCFCL.
As our patient had a disseminated cutaneous form of
the disease involving multiple anatomic regions, we de-
cided on the use of superficial fractionated radiotherapy
[1,4,13-15,46-51], administered upon eight fields in VI
expositions, with total irradiation dose of 1400 cGy, on
the following irradiation fields: left and right pectoral
region, left and right shoulder, right suprascapular
region, and proximal third of the right forearm. Total
dose received per field upon lesions on the left and right
side of the back was 1500 cGy. This therapy resulted in
significant reduction of visible tumor [Figures 6 and 7.
Post-radiotherapy skin appearance]. The patient was regu-
larly followed up for 12months following radiotherapy
and remained free from local relapse or extracutaneous
dissemination of the disease. Staging of the disease can be
repeated in case of relapse or every 12 months (heart and
lung x-ray is usually repeated every 2–3 years).
Conclusion
In the patient presented, the diagnosis of PCFCL with
follicular growth pattern was made by complete work-up
and exclusion of systemic disease. Although it is an
indolent B-cell lymphoma, appropriate approach to the
patient and complete diagnostic work-up are necessary
as in all cutaneous lymphomas. Close collaboration ofspecialists in dermatology, pathology, cytology and
hematology is of utmost importance to reach an accurate
diagnosis, to perform proper disease staging, and to
choose the most suitable therapeutic modality.
Of the known therapeutic procedures, we decided to
use superficial fractionated radiotherapy upon eight
fields, which led to the significant reduction of visible
tumor.
Patients with this type of cutaneous lymphoma have
good prognosis, with the expected 5-year survival of
95% and rare systemic disease development. Skin re-
lapses are reported in 20% of cases and are treated with
radiotherapy. Our patient has been on regular follow up
for possible skin relapses or extracutaneous disease
dissemination.
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